Literature DB >> 19035224

[The impact of antibiotic treatment in patients with influenza-like illness].

Bin Cao1, Ran Li, Ying-Mei Liu, Zhi-Xin Cao, Xiu-Qin Geng, Lok-Ting Lau, Jie Lu, Lin Wu, Shu-Feng Cui, Rui-Ting Bai, Chang-Hai Yu, Chen Wang.   

Abstract

OBJECTIVE: To study the etiology of influenza-like illness (ILI) in Beijing, and to investigate the impact of antibiotic treatment on outcomes.
METHODS: This was a prospective cohort study. Patients with diagnosis of influenza-like illness were prospectively enrolled for study of bacterial and viral pathogens. Demographic characteristics, underlying diseases, respiratory and extrapulmonary symptoms, laboratory tests were also collected for analysis of relationship between drug therapy and outcomes.
RESULTS: A total of 476 cases were enrolled between Dec. 2006 and Apr. 2007, of whom 454 cases were used for analysis. Influenza virus was the most common pathogen( n = 197, 43.4%), with other pathogens rarely seen. The mean age of the patients was (33 +/- 13) years, and the ratio of male to female was 1.1:1. Twenty four patients (5.3% ) received influenza vaccine. The rate of antibiotic prescription after onset of illness was 63.4%, but none received antiviral drugs such as Oseltamivir and amantadine. Compared with influenza-negative patients, patients with influenza were older, had more underlying diseases and had greater severity of symptoms such as cough, sore throat, headache and myalgia (but with no statistical differences). The influenza syndrome (T > or = 39 degrees C plus cough, sore throat and headache or myalgia) was more common in the influenza group compared to the influenza-negative patients (P < 0.05). The ratio of antibiotic prescription was 67% in the influenza group, and the total white blood cell and platelet count, percentage of neutrophils were higher in antibiotic treatment patients compared with non-antibiotic treatment patients (P < 0.01). The cost in patients who received antibiotics was twice as much as non-antibiotic treatment patients (P < 0.05), but the defervescence time and respiratory symptom alleviation time did not differ. Cox regression analysis showed that the total white blood count and the differentials (OR value 1.049 and 1.014, respectively), but not antibiotic use were the independent risk factors for longer defervescence time.
CONCLUSION: Influenza virus was the most common pathogen for adult patients with ILI in Beijing city during the winter and the spring seasons. Antibiotic treatment of adult patients with ILI did not improve illness resolution, while the cost was increased significantly.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035224

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  4 in total

1.  Trends of out-of-pocket expenditure for influenza in China Health and Nutrition Survey during 1989-2006.

Authors:  Jinan Liu; Lizheng Shi; Mahmud Khan; Lingzhong Xu; Liya Wang
Journal:  Int J Public Health       Date:  2011-04-19       Impact factor: 3.380

2.  Etiology and clinical characteristics of influenza-like illness (ILI) in outpatients in Beijing, June 2010 to May 2011.

Authors:  XiaoHua Yang; Yao Yao; MeiFang Chen; Xia Yang; YanDi Xie; YaFen Liu; XiuYing Zhao; Yan Gao; Lai Wei
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

3.  The association between influenza treatment and hospitalization-associated outcomes among Korean children with laboratory-confirmed influenza.

Authors:  Jacqueline K Lim; Tae Hee Kim; Paul E Kilgore; Allison E Aiello; Byung Min Choi; Kwang Chul Lee; Kee Hwan Yoo; Young-Hwan Song; Yun-Kyung Kim
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

4.  Patterns of medication use and factors associated with antibiotic use among adult fever patients at Singapore primary care clinics.

Authors:  Zaw Myo Tun; Mahesh Moorthy; Martin Linster; Yvonne C F Su; Richard James Coker; Eng Eong Ooi; Jenny Guek-Hong Low; Gavin J D Smith; Clarence C Tam
Journal:  Antimicrob Resist Infect Control       Date:  2016-11-24       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.